SIREN : 812109635
ATA PHARMA is a French company founded 10 years ago, specialized in the sector Entreposage et stockage non frigorifique. Based in LE VAUDREUIL (27100), this company of category PME shows in 2024 a revenue of 5.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2019 | 2017 |
|---|---|---|---|---|---|
| Revenue | 5 839 723 € | 5 152 781 € | 4 188 360 € | 2 397 406 € | 812 645 € |
| Net income | 585 275 € | 306 043 € | 291 043 € | 263 252 € | -61 863 € |
| EBITDA | 979 726 € | 567 684 € | 498 117 € | 336 280 € | -41 878 € |
| Net margin | 10.0% | 5.9% | 6.9% | 11.0% | -7.6% |
In 2024, ATA PHARMA achieves revenue of 5.8 M€. Over the period 2017-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +32.5%. Vs 2023, growth of +13% (5.2 M€ -> 5.8 M€). After deducting consumption (0 €), gross margin stands at 5.8 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 980 k€, representing 16.8% of revenue. Positive scissor effect: EBITDA margin improves by +5.8 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 585 k€, i.e. 10.0% of revenue. This profit can be retained or distributed to shareholders.
5 839 723 €
5 839 723 €
979 726 €
778 340 €
585 275 €
16.8%
The debt ratio (= Financial debt / Equity x 100) stands at 19%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 64%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.6 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 12.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
19.318%
64.465%
12.536%
0.631
69.0%
In 2024, the debt ratio of ATA PHARMA (19.32) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of ATA PHARMA (64.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of ATA PHARMA (0.63) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 282.86. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.8x. Coverage is limited: any activity downturn would jeopardize interest payments.
282.864
1.807
In 2024, the liquidity ratio of ATA PHARMA (282.86) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of ATA PHARMA (1.8x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 58 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 26 days. The gap of 32 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 39 days of revenue, i.e. 637 k€ to permanently finance. Over 2017-2024, WCR increased by +315%, requiring additional financing.
637 114 €
58 j
26 j
0 j
39 j
Based on 77 transactions of similar company sales
(all years),
the value of ATA PHARMA is estimated at
889 535 €
(range 433 868€ - 2 302 611€).
With an EBITDA of 979 726€, the sector multiple of 1.0x is applied.
The price/revenue ratio is 0.14x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 77 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ATA PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Entreposage et stockage non frigorifique
The revenue of ATA PHARMA in 2024 is 5.8 M€.
Yes, ATA PHARMA generated a net profit of 585 k€ in 2024.
The headquarters of ATA PHARMA is located in LE VAUDREUIL (27100), in the department Eure.
The tax return of ATA PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ATA PHARMA operates in the sector Entreposage et stockage non frigorifique (NAF code 52.10B). See the 'Sector positioning' section above to compare the company with its competitors.